AWKN Stock Overview
Awakn Life Sciences Corp., a biotechnology company, engages in the researching, developing, operations, and delivering of psychedelic therapeutics to treat addiction and other mental health conditions in the United Kingdom and Europe.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Awakn Life Sciences Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.17 |
| 52 Week High | CA$0.77 |
| 52 Week Low | CA$0.055 |
| Beta | 3.11 |
| 1 Month Change | -7.89% |
| 3 Month Change | -37.50% |
| 1 Year Change | -43.55% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -91.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| AWKN | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | -16.7% | -0.4% | -1.8% |
| 1Y | -43.5% | 19.3% | 24.6% |
Return vs Industry: AWKN underperformed the Canadian Biotechs industry which returned 19% over the past year.
Return vs Market: AWKN underperformed the Canadian Market which returned -1.2% over the past year.
Price Volatility
| AWKN volatility | |
|---|---|
| AWKN Average Weekly Movement | 46.2% |
| Biotechs Industry Average Movement | 12.3% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CA Market | 17.9% |
| 10% least volatile stocks in CA Market | 3.5% |
Stable Share Price: AWKN is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 46% a week.
Volatility Over Time: AWKN's weekly volatility has increased from 30% to 46% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 44 | Anthony Tennyson | https://awaknlifesciences.com |
Awakn Life Sciences Corp., a biotechnology company, engages in the researching, developing, operations, and delivering of psychedelic therapeutics to treat addiction and other mental health conditions in the United Kingdom and Europe. The company has a collaboration agreement with the University of Exeter for exploring the use of ketamine-assisted therapy to treat Severe AUD. Awakn Life Sciences Corp. is headquartered in Toronto, Canada.
Awakn Life Sciences Corp. Fundamentals Summary
| AWKN fundamental statistics | |
|---|---|
| Market Cap | CA$6.17m |
| Earnings (TTM) | -CA$7.53m |
| Revenue (TTM) | CA$1.53m |
4.4x
P/S Ratio-0.9x
P/E RatioIs AWKN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AWKN income statement (TTM) | |
|---|---|
| Revenue | CA$1.53m |
| Cost of Revenue | CA$3.05m |
| Gross Profit | -CA$1.52m |
| Other Expenses | CA$6.01m |
| Earnings | -CA$7.53m |
Last Reported Earnings
Jul 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.20 |
| Gross Margin | -99.09% |
| Net Profit Margin | -491.55% |
| Debt/Equity Ratio | 0% |
How did AWKN perform over the long term?
See historical performance and comparison